Immunotherapy is a treatment that utilizes few parts of a person’s immune system to fight diseases, such as cancer. This can be done either by enhancing one’s immune system to function harder and smarter to fight cancer cells or by providing immune system components, such as human-made immune system proteins.  Cancer immunotherapy fuels the body's natural defenses to struggle against cancer. Immunotherapy is a type of biological therapy. The increasing incidences of cancer day by day, raising awareness about the early diagnosis among cancer patients, efficacy of the therapy compared to other therapies, treatment of cancer amongst the people across the world, and surging geriatric population are some of the primary factors propelling the growth of the global cancer immunotherapy market. Apart from that, the factors that hamper the cancer immunotherapy market are high costs in the treatment and new drugs. The Cancer Immunotherapy Market is projected to grow at the rate of 9.7% CAGR by 2026.

Research Methodology:

The Cancer Immunotherapy Market has been analyzed by utilizing the optimum combination of secondary sources and in-house methodology and a unique balance of primary insights. The real-time valuation of the market is an integral part of our forecasting and market sizing methodology. Industry experts and our primary participants have helped to compile related aspects with accurate parametric estimations for a complete study. The primary participants share is given below:

Cancer Immunotherapy Market segmentation by Product Type

• Monoclonal Antibodies
• Cancer Vaccines
• Check Point Inhibitors
• Immunomodulators

Cancer Immunotherapy Market segmentation by Application

• Lung cancer
• Breast cancer
• Head and neck cancer
• Prostate cancer
• Colorectal cancer
• Melanoma
• Others

Cancer Immunotherapy Market segmentation by End Users

• Hospitals & clinic
• Diagnostic centers

Cancer Immunotherapy Market segmentation by Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

The product type segment of the cancer immunotherapy market is sub-segmented as Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors, and Immunomodulators. Among all product types, the monoclonal segments are having a key share in the market. Rising investments in research and development of monoclonal antibodies since naked antigen-binding antibodies, conjugated monoclonal antibodies, and bispecific antibodies have opened new revenue creation paths for companies that offer oncology therapeutics. These R&D activities lead to the emergence of monoclonal antibodies and owing to various benefits of mAbs they are being examined for various treatments.

If analyzed by the application, the immunotherapy treatment is majorly used to treat lung cancer. The lung cancer segment has the maximum share occupied in the cancer immunotherapy market. This is due to the increasing number of smokers worldwide, a major cause for lung cancer, giving rise to the number of lung cancer cases.

As per the end-user, the cancer immunotherapy market is majorly bifurcated into hospitals & clinics, and diagnostic centers. The hospitals and clinics segment is anticipated to have the fastest growth due to the rising patient pool. Most of the hospitals, specifically in cancer immunotherapy, focus on the treatment of symptomatic conditions. The hospitals and clinics offer cutting-edge treatments which use a patient's immune system to fight cancer. These include cellular therapies, cancer vaccines, and other experimental drugs.

As observed, the North American region is dominating the cancer immunotherapy market due to the rising demand for immunotherapy, increased technological advancements in the treatment of cancer, and the increasing rate of cancer in this region. Thus factors mentioned above are mainly contributing to the market growth.

Immunotherapies in the pipeline are happening to provide more treatment choices and better results than prevailing therapies. The emergence of new drug classes, such as monoclonal antibodies and histone deacetylase (HDAC) inhibitors, designed to target receptors associated with multiple myeloma, is expected to build the market's future. Ongoing studies on similar drugs aim to reduce adverse effects and are anticipated to spur the market's growth.

These are the primary cancer immunotherapy market players -Merck & Co., Inc., Novartis Pharmaceuticals Corporation, F. Hoffmann-La Roche AG, Advaxis Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Pfizer Inc., Bayer AG, Immunomedics Inc., and AstraZeneca plc.

Hence, cancer immunotherapy is observed to be playing a crucial role in cancer treatment. With the considerable pressure of increasing cancer cases and the side effects of other therapies, cancer immunotherapy has exhibited tremendous potential over the past few years.

• The profiles of key vendors are presented in the report coupled with their latest developments, which gives a better perception of the competition
• The report also gives a complete perception of the cancer immunotherapy market with the insights such as drivers, opportunities, challenges, trends, and growth of the market.
• This report also depicts the key factors and challenges encountered by the key vendors and the forthcoming impact of the restraints and opportunities on the key players.
• Further entails analyzing the past and presenting cancer immunotherapy market size and further penetrating the market worldwide.   

1. Executive Summary
2. Industry Outlook
   1. Industry Overview
   2. Industry Trends
3. Market Snapshot
   1. Market Definition
   2. Market Outlook
      1. Porter Five Forces
   3. Related Markets
4. Market characteristics
   1. Market Overview
   2. Market Segmentation
   3. Market Dynamics
      1. Drivers
      2. Restraints
      3. Opportunities
   4. DRO - Impact Analysis
5. Product Type: Market Size & Analysis
   1. Overview
   2. Monoclonal Antibodies
   3. Cancer Vaccines
   4. Check Point Inhibitors
   5. Immunomodulators
6. Application: Market Size & Analysis
   1. Overview
   2. Lung cancer
   3. Breast cancer
   4. Head and neck cancer
   5. Prostate cancer
   6. Colorectal cancer
   7. Melanoma
   8. Others
7. End Users: Market Size & Analysis
   1. Overview
   2. Hospitals & clinic
   3. Diagnostic centers
8. Geography: Market Size & Analysis
   1. Overview
   2. North America
   3. Europe
   4. Asia Pacific
   5. Rest of the World
9. Competitive Landscape
   1. Competitor Comparison Analysis
   2. Market Developments
      1. Mergers and Acquisitions, Legal, Awards, Partnerships
      2. Product Launches and execution
10. Vendor Profiles
    1. Merck & Co., Inc.
       1. Overview
       2. Financial Overview
       3. Product Offerings
       4. Developments
       5. Business Strategy
    2. Novartis Pharmaceuticals Corporation
       1. Overview
       2. Financial Overview
       3. Product Offerings
       4. Developments
       5. Business Strategy
    3. F. Hoffmann-La Roche AG, Advaxis Inc.
       1. Overview
       2. Financial Overview
       3. Product Offerings
       4. Developments
       5. Business Strategy
    4. Advaxis Inc.
       1. Overview
       2. Financial Overview
       3. Product Offerings
       4. Developments
       5. Business Strategy
    5. Bristol-Myers Squibb Company
       1. Overview
       2. Financial Overview
       3. Product Offerings
       4. Developments
       5. Business Strategy
    6. Eli Lilly and Company
       1. Overview
       2. Financial Overview
       3. Product Offerings
       4. Developments
       5. Business Strategy
    7. Pfizer Inc.
       1. Overview
       2. Financial Overview
       3. Product Offerings
       4. Developments
       5. Business Strategy
    8. Bayer AG
       1. Overview
       2. Financial Overview
       3. Product Offerings
       4. Developments
       5. Business Strategy
    9. Immunomedics Inc.
       1. Overview
       2. Financial Overview
       3. Product Offerings
       4. Developments
       5. Business Strategy
    10. AstraZeneca plc.
        1. Overview
        2. Financial Overview
        3. Product Offerings
        4. Developments
        5. Business Strategy
11. Analyst Opinion
12. Annexure
    1. Report Scope
    2. Market Definitions
    3. Research Methodology
       1. Data Collation and In-house Estimation
       2. Market Triangulation
       3. Forecasting
    4. Report Assumptions
    5. Declarations
    6. Stakeholders
    7. Abbreviations